MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS
MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm…
Cancer-infecting virus ‘warms up’ cold tumors and improves immunotherapy
Cancer-infecting virus ‘warms up’ cold tumors and improves immunotherapy Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear…
Pfizer’s ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma
Pfizer’s ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to…
Novartis Completes Acquisition of Chinook Therapeutics
Novartis Completes Acquisition of Chinook Therapeutics Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development,…
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria Novartis today announced positive top-line results from the Phase III REMIX-1 and…
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes, and other serious metabolic diseases
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases Novo Nordisk A/S and Inversago Pharma today announced that…
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novo Nordisk today announced…
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the…
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Biogen Inc. (Nasdaq: BIIB) and Sage…
AI drives a new era of target identification and drug design
AI drives a new era of target identification and drug design Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial…
Learning how to control HIV from African genomes
Learning how to control HIV from African genomes Despite significant advances in treatment and access to therapy, the human immunodeficiency virus remains a global health challenge with almost 40 million…
New RNA-based therapy combats melanoma in mouse models
New RNA-based therapy combats melanoma in mouse models Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells – which…